Regeneron reached an agreement with the U.S. government to link current and future drug prices to those in other developed countries, while also making its newly approved gene therapy Otarmeni free to U.S. patients with an ultra-rare inherited hearing loss.

The agreement also includes direct-purchase availability for Praluent, a cholesterol-lowering medicine, through TrumpRx.gov, according to the company’s statement. Additional terms were not disclosed.¹

“For too long, American patients and taxpayers have shouldered a disproportionate share of the cost of biotechnology innovation, effectively subsidizing lower drug prices for other high-income nations that have not been paying their fair share,” said Dr. Leonard Schleifer, board co-chair, president and chief executive officer. “Vilifying the biopharma industry has not produced lower prices for Americans, nor has it generated more innovation. For more than a decade, we have argued that the most direct path to meaningful relief for American patients depends on getting other high-income countries to finally contribute their fair share to the cost of the breakthroughs they rely on just as much as we do. We hope that today’s agreement, coupled with effective trade policy, will lead to closer equilibration of prices around the globe while preserving innovation and lowering prices for Americans.”¹

What does Regeneron’s agreement mean for pharmaceutical market access strategy?

According to Regeneron, the deal is expected to lower Medicaid prices using prices in other developed countries as a benchmark while also aligning future U.S. prices with prices in the same group of countries.¹

The significance of the deal lies less in the immediate effect on one manufacturer and more so in the policy signal of drug pricing discussions that are moving beyond rebate design and the Inflation Reduction Act-era negotiation frameworks and more towards a direct international price reference.

If adopted more broadly, the approach could affect launch sequencing, ex-U.S. pricing decisions and contracting strategy. It may also sharpen debates over whether U.S. revenue continues to underwrite global research and development spending.

The agreement also offers Regeneron relief from future pricing mandates and tariffs for three years through a Commerce Department arrangement tied to domestic research, development and manufacturing activity.¹ The agreement addressed the four requests previously send by President Trump in letters to large pharmaceutical companies back in July of 2025.

The combination of price concessions and industrial policy holds the potential to be relevant for biopharmaceutical manufacturers who are weighing capital allocation in U.S. production networks, as in recent years, supply-chain resilience and domestic biologics manufacturing have become more central to federal policy and investor scrutiny.²

Why is Otarmeni’s free-access plan important?

The second major element of the announcement focuses on Otarmeni, or lunsotogene parvec-cwha, which was recently approved by FDA for people with severe to profound hearing loss due to variants in the otoferlin gene.¹ The company says it is planning to provide the treatment for free in the United States.¹

The decision marks a milestone, as gene therapies have faced persistent access barriers due to high upfront cost, benefit uncertainty in small populations, and operational complexity around referral, treatment-site readiness and reimbursement.³ In ultra-rare disease, those barriers can be magnified because health systems may have limited experience identifying eligible patients.

In a statement emailed to Pharmaceutical Executive, Dr. George Yancopoulos, board co-chair, president and chief scientific officer of Regeneron noted, "We are proud to provide Otarmeni, a life-changing new gene therapy, for free in the U.S. As we saw the amazing Chord clinical data, we had many discussions internally about how to make sure this scientific breakthrough would be able to reach its full potential and help as many people as possible. Our unprecedented offering reflects how Regeneron is a very different type of company, and is willing to do things that others wouldn't even consider, to highlight our commitment and mission of using the power of science to make a real difference for humanity."

The announcement did not provide clinical data, safety findings or prescribing details, limiting assessment of how the therapy may compare with other interventions used in congenital hearing loss.

Regeneron’s free-access model is expected to be watched closely as a potential alternative for selected ultra-rare products where traditional reimbursement frameworks are difficult to sustain.³

How could this affect the broader cardiovascular drug pricing landscape?

Regeneron also announced that eligible patients will be able to directly purchase Praluent, or alirocumab, at the most-favored-nation price through TrumpRx.gov.¹

Praluent is a proprotein convertase subtilisin/kexin type 9 inhibitor used to reduce low-density lipoprotein cholesterol in appropriate patients and has previously been part of broader payer access and affordability debates in cardiovascular care.⁴

What are the main uncertainties with the agreement?

The announcement leaves several unanswered questions, including, an undefined set of comparator countries to base prices off of, unknown mechanics for Medicaid repricing, a defined scope of “future medicines,” or the financial implications of tariff relief and protection from future pricing mandates.¹

Implementation details will determine whether this becomes a one-off agreement or a template with implications for launch economics, cross-border reference pricing and domestic manufacturing commitments.

Sources

1. Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S. GlobeNewswire. April 23, 2026. Accessed April 24, 2026. https://www.globenewswire.com/news-release/2026/04/23/3280340/0/en/regeneron-announces-agreement-with-u-s-government-to-help-lower-drug-costs-for-american-patients-and-will-provide-innovative-new-gene-therapy-for-free-in-the-u-s.html
2. U.S. Food and Drug Administration. Resilient Supply Chain Program for Critical Medicines. FDA. Accessed April 24, 2026.
3. U.S. Food and Drug Administration. Human Gene Therapy Products: Incorporating Human Genome Editing Into Gene Therapy Products; Guidance for Industry. FDA. Accessed April 24, 2026.
4. Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab added to high-intensity statin therapy on cardiovascular events in patients after acute coronary syndrome: the ODYSSEY OUTCOMES randomized clinical trial. N Engl J Med. 2018;379(22):2097-2107. doi:10.1056/NEJMoa1801174